ACR Convergence 2025 Preview

Questions discussed in this category

Do GLP-1 agonists have measurable anti-inflammatory effects in diseases like RA or spondyloarthropathies beyond weight loss?

This question is part of our collaboration with ACR Convergence 2025 to preview a session from this year's meeting. This question is inspired by the u...

1 Answer available

Do you have safety concerns when prescribing GLP-1 medications in patients on corticosteroids or immunosuppressive therapy?

This question is part of our collaboration with ACR Convergence 2025 to preview a session from this year's meeting. This question is inspired by the u...

1 Answer available

What is the role of the rheumatologist in recommending and providing GLP-1 medications to their patients given the benefits across many disease domains including osteoarthritis?

This question is part of our collaboration with ACR Convergence 2025 to preview a session from this year's meeting. This question is inspired by the u...

2 Answers available

Papers discussed in this category

Life (Basel, Switzerland), 2023 Jul 28

The New England journal of medicine, 2024 Oct 31

Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis.

ACR Convergence 2025 Preview

Questions discussed in this category

Papers discussed in this category

Related Topics